IL-17 and IL-23(p19) inhibitors as effective as TNF inhibitors in PsAOctober 23, 2023Psoriatic Arthritis
Bimekizumab offers sustained clinical response in bDMARD-naive PsA patientsOctober 23, 2023Psoriatic Arthritis
Rheumatology NewsFDA approves bimekizumab for moderate to severe plaque psoriasis in adultsOctober 19, 2023Psoriatic Arthritis
Rheumatology NewsPilot study: High-dose IL-23 inhibition shows promise for psoriasis remission in some patientsOctober 19, 2023Psoriatic Arthritis
Rheumatology NewsApproximately 20% of U.S. adults are diagnosed with arthritisOctober 18, 2023OsteoarthritisRheumatoid ArthritisPsoriatic ArthritisSpondyloarthropathiesAnkylosing spondylitisLupus & Connective Tissue DiseasesGout
Rheumatology NewsRoflumilast side effect benefits patients with psoriasis and overweight/obesityOctober 16, 2023Psoriatic Arthritis
Rheumatology NewsPediatric psoriasis: Black children, males more likely to have palmoplantar subtype, study findsOctober 12, 2023PediatricsPsoriatic ArthritisDiversity in Medicine
Rheumatology NewsIntravenous formulation of secukinumab gets FDA approvalOctober 10, 2023Psoriatic ArthritisSpondyloarthropathiesPediatricsAnkylosing spondylitis
Rheumatology NewsChoosing which biologic to prescribe for psoriasisOctober 6, 2023Psoriatic Arthritis
Rheumatology NewsFDA approves topical roflumilast for psoriasis in children aged 6-11October 6, 2023PediatricsPsoriatic Arthritis
Rheumatology NewsFDA approves ninth Humira biosimilar, with interchangeabilityOctober 6, 2023Rheumatoid ArthritisPsoriatic ArthritisPediatricsSpondyloarthropathiesAnkylosing spondylitis
Commentary: DMARD types, guselkumab, and interleukin inhibitors in PsA, October 2023September 27, 2023Psoriatic Arthritis
Tofacitinib can be considered as a treatment option for PsA with enthesitisSeptember 21, 2023Psoriatic Arthritis
Secukinumab offers sustained improvement in synovitis and enthesitis in active PsASeptember 21, 2023Psoriatic Arthritis
